Last reviewed · How we verify
Belimumab plus Late Vaccination — Competitive Intelligence Brief
marketed
Biologic
Live · refreshed every 30 min
Target snapshot
Belimumab plus Late Vaccination (Belimumab plus Late Vaccination) — Human Genome Sciences Inc., a GSK Company.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Belimumab plus Late Vaccination TARGET | Belimumab plus Late Vaccination | Human Genome Sciences Inc., a GSK Company | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Belimumab plus Late Vaccination CI watch — RSS
- Belimumab plus Late Vaccination CI watch — Atom
- Belimumab plus Late Vaccination CI watch — JSON
- Belimumab plus Late Vaccination alone — RSS
Cite this brief
Drug Landscape (2026). Belimumab plus Late Vaccination — Competitive Intelligence Brief. https://druglandscape.com/ci/belimumab-plus-late-vaccination. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab